In addition, the therapeutic efficacy of PD-L1 checkpoint blockade immunotherapy is greater in Ythdf1–/– mice than wild-type mice, thus indicating that YTHDF1 is a potential therapeutic target in anti-tumor immunotherapy45. Here, CD274 is linked to neoplasm.